全文获取类型
收费全文 | 345篇 |
免费 | 67篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
基础医学 | 6篇 |
口腔科学 | 5篇 |
临床医学 | 108篇 |
内科学 | 107篇 |
神经病学 | 8篇 |
特种医学 | 3篇 |
外科学 | 14篇 |
综合类 | 17篇 |
预防医学 | 9篇 |
眼科学 | 1篇 |
药学 | 141篇 |
中国医学 | 2篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 7篇 |
2022年 | 22篇 |
2021年 | 41篇 |
2020年 | 40篇 |
2019年 | 34篇 |
2018年 | 36篇 |
2017年 | 35篇 |
2016年 | 31篇 |
2015年 | 24篇 |
2014年 | 36篇 |
2013年 | 79篇 |
2012年 | 20篇 |
2011年 | 8篇 |
2010年 | 4篇 |
2009年 | 4篇 |
2008年 | 2篇 |
2007年 | 1篇 |
排序方式: 共有424条查询结果,搜索用时 15 毫秒
81.
目的研究利伐沙班的出血副作用,并对其拮抗剂对大鼠出血模型的影响进行探索。方法大鼠ig给予不同剂量利伐沙班(0.3~30 mg/kg)1.5 h后,根据断尾法测定的出血时间、出血量,以及凝固法测定的血浆凝血酶原时间(PT),观察其出血副作用;大鼠ig给予大剂量利伐沙班(30 mg/kg)制备大鼠出血模型,尾iv人凝血酶原复合物或白眉蛇毒血凝酶,通过测定大鼠断尾出血时间、出血量以及血浆PT,观察两种药物对出血作用的拮抗效果。结果大鼠ig给予不同剂量的利伐沙班后,出血时间、出血量、血浆PT都明显增加,与利伐沙班的剂量呈正相关;人凝血酶原复合物能够显著抑制利伐沙班所致的出血时间、出血量和血浆PT的增加,而白眉蛇毒血凝酶对上述指标无明显影响。结论利伐沙班存在剂量相关性的出血副作用,在出血严重时,可采用人凝血酶原复合物作为拮抗剂进行治疗。 相似文献
82.
心房颤动是常见的心律失常疾病,持续48 h即可形成血栓,血栓脱落可导致动脉栓塞,其中90%是缺血性脑卒中,而慢性肾脏疾病可进一步增加房颤患者的卒中和出血风险。因此,在伴有慢性肾脏疾病的非瓣膜性房颤患者中的抗凝尤为重要。华法林用于肾功能不全的房颤患者虽可减少血栓栓塞的发生率,但是随着肾功能的恶化,华法林可增加出血的风险,且维持国际标准化比值(INR)在目标范围的时间非常困难。与华法林相比,新型口服抗凝药物能显著地降低卒中、颅内出血和死亡风险。然而新型口服抗凝药物在轻度、中度、重度,甚至血液透析房颤患者的应用仍存在争议。 相似文献
83.
V. PENGO L. CRIPPA A. FALANGA G. FINAZZI F. MARONGIU M. MOIA G. PALARETI D. POLI S. TESTA E. TIRAFERRI A. TOSETTO A. TRIPODI S. SIRAGUSA C. MANOTTI 《Journal of thrombosis and haemostasis》2012,10(10):1979-1987
Summary. In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation. Strengths and weaknesses of the studies were examined in detail through indirect comparison. We analyze and comment the inclusion and exclusion criteria, the characteristics of randomized patients, the primary efficacy and safety end points and side effects. All new oral anticoagulants resulted in being non‐inferior to vitamin K antagonists in reducing stroke or systemic embolism in patients with atrial fibrillation. Dabigatran 150 mg and apixaban were superior to vitamin K antagonists. Importantly, new oral anticoagulants significantly reduced hemorrhagic stroke in all three studies. Major differences among new oral anticoagulants include the way they are eliminated and side effects. Both dabigatran and apixaban were tested in low‐ to moderate‐risk patients (mean CHADS2 [Congestive heart failure, Hypertension, Age, Diabetes, Stroke] score = 2.1–2.2) whereas rivaroxaban was tested in high‐risk patients (mean CHADS2 score = 3.48) and at variance with dabigatran and apixaban was administered once daily. Apixaban significantly reduced mortality from any cause. The choice of a new oral anticoagulant should take into account these and other differences between the new drugs. 相似文献
84.
Verheugt FW 《Fundamental & clinical pharmacology》2012,26(1):11-15
Vitamin K antagonists have been used as oral anticoagulants (OACs) for over five decades, yet their use in real-world practice is problematic primarily because of their narrow therapeutic window, exacerbated by extensive food and drug interactions, necessitating regular coagulation monitoring and dose adjustment. Around half of patients receiving warfarin are within the therapeutic range, exposing them to the dangers of under-anticoagulation (i.e. thrombosis formation) or over-anticoagulation (i.e. bleeding). A new generation of OACs with improved pharmacology promises to revolutionize antithrombotic management. Rivaroxaban, apixaban (both oral direct Factor Xa inhibitors) and dabigatran (a direct thrombin inhibitor) all exhibit predictable anticoagulant responses and few drug-drug interactions and do not require routine coagulation monitoring. 相似文献
85.
Introduction: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the western world. The approval of non-vitamin K oral anticoagulants (NOACs) as antithrombotic alternatives to vitamin K antagonists (VKAs) has offered more treatment options to physicians for the prevention of VTE recurrence, fatal pulmonary embolism (PE) and long-term complications. Four NOACs (dabigatran, rivaroxaban, apixaban and edoxaban) that have been approved for the treatment of acute VTE following large phase III trials, where NOACs demonstrated similar efficacy and superior safety profile compared to VKAs.Areas covered: The purpose of this review article is to summarise current knowledge of oral anticoagulation for the treatment of acute VTE and to compare NOACs with VKAs, highlighting the factors that might influence the decisions of physicians. Data for this article were obtained through a search of PubMed for trials comparing NOACs with VKAs in acute VTE setting and articles or analyses that interpreted results from these trials.Expert opinion: The NOACs have changed clinical practice regarding oral anticoagulation for acute VTE. Despite their advantages, ‘grey zones’ still remain and more studies are needed to provide evidence and confirm the superiority (or at least non-inferiority) of NOACs over VKAs. Real world data might give additional insights. 相似文献
86.
The introduction of direct oral anticoagulant (DOAC) therapy into clinical use in the past 5 years has had significant impact on the clinical laboratory. Clinicians’ desire to determine plasma drug presence or measure drug concentration, and more recent observations regarding the limitations and utility of coagulation testing in the setting of DOAC treatment, suggest that early published recommendations regarding laboratory testing should be reassessed. These initial recommendations, furthermore, were often based on drug‐spiked plasma studies, rather than samples from patients receiving DOAC therapy. We have demonstrated that reagent sensitivity varies significantly whether drug‐spiked samples or samples from DOAC‐treated patients are tested. Data from drug‐enriched samples must therefore be interpreted with caution or be used as a guide only. We present laboratory assays that can be used to determine drug presence and to measure drug concentration, and provide recommended testing algorithms. As DOAC therapy may significantly impact on specialty coagulation assays, we review those tests with the potential to give false‐positive and false‐negative results. 相似文献
87.
88.
89.
C. Kluft P. Meijer R. Kret J. Burggraaf 《International journal of laboratory hematology》2013,35(4):379-384
90.
《Expert opinion on investigational drugs》2013,22(6):925-937
Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists. Rivaroxaban is being investigated for the prevention and treatment of venous and arterial thrombosis. A broad search of Medline, clinicaltrials.gov and the annual proceedings of the American Society of Hematology and the International Society on Thrombosis and Hemostasis was conducted. This review addresses the findings of this systematic search, including the need for new oral anticoagulants, the development and pharmacology of rivaroxaban, and the results of completed as well as ongoing trials with rivaroxaban. At present, the safety and efficacy of rivaroxaban for the prophylaxis and treatment of venous thromboembolism has been evaluated in Phase II and Phase III trials involving over 24,000 patients. Additionally, rivaroxaban is being evaluated for the treatment of pulmonary embolism, secondary prevention after acute coronary syndromes and the prevention of stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation. The drug may have its greatest impact in providing a much-needed and attractive alternative to warfarin. Further data (especially large Phase III trials) are required. 相似文献